34results about How to "Improve lipid metabolism disorder" patented technology

The invention discloses lactobacillus rhamnosus CCFM1060, a fermented food and a preparation method of a bacterial agent; increase of the abundance of Proteus induced by high lipid and high cholesterol diet is significantly reduced, and the occurrence of diseases such as urinary tract blockage, intestinal bacterial migration and enteritis is reduced; the lipid metabolism disorder of NAFLD patientsis significantly improved; insulin resistance of NAFLD mice is significantly improved; increase of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase in serum can be re-adjusted; theconcentration of low-density lipoprotein cholesterol is significantly reduced, and the risk of cardiovascular disease is reduced; the level of SOD in liver of NAFLD patients can be significantly improved; the inflammation of liver can be significantly improved; the damage of liver tissues of the NAFLD patients can be significantly improved; the expression of an Nrf2 gene in fatty liver cells can be significantly improved; the ability to absorb perfluorooctanoic acid in vitro is strong.

The invention relates to a method for preparing salvia miltiorrhizae phenolic acid and its new application in medicine production field. The method comprises following steps: adding water or alcohol into salvia miltiorrhizae for extraction, purifying phenolic acid through column chromatography and purification; washing with alcohol solution, condensing washing solution; adjusting pH, extracting with organic solvent, condensing and drying, getting salvia miltiorrhizae phenolic acid with salvia miltiorrhizae phenolic acid A and B content being above 90%. It is proven by medical effect and pharmacological research that the salvia miltiorrhizae phenolic acid can be used to prepare medicine that treats type-2 diabetes and its complication, including diabetes kidney disease, hepatic disease, and blood rheological property change caused by diabetes. It is tested that the effect of salvia miltiorrhizae phenolic acid and its preparation is strong, and they are safe medicine.

The present invention discloses anti-aging yoghurt containing modified starch and a preparation method thereof. The anti-aging yoghurt containing the modified starch comprises the following raw materials in parts by weight: 40-100 parts of bovine colostrum, 10-30 parts of fish collagen peptide powder, 1-5 parts of a thickener, 2-6 parts of concentrated fruit juice, 0.5-1.5 parts of tea polyphenol nanoparticles, 0.1-1 part of a sweetener and 0.1-1 part of probiotics. The thickener is composed of sodium alginate and modified starch according to a mass ratio of 1:(4-6). The anti-aging yoghurt containing the modified starch is rich in nutrients, delicate in mouthfeel, smooth and refreshing, has effects of regulating balance of human body intestinal micro-ecology, improving intestinal functions, lowering blood lipids and lowering blood pressure, enhancing human body immunity and delaying aging, and is simple and easy to implement in the preparation method, strong in operability, low in cost and suitable for factory production applications.

The invention discloses a medicine for treating fatty liver and hyperlipidaemia and a preparation process thereof. The medicine preparation is prepared from ginseng, silybum marianum, salvia miltiorrhiza and hawthorn by the scientific preparation process and can be used for treating fatty liver diseases. The medicine is characterized in that the pure traditional Chinese medicines are selected and prepared into the preparation, and the medicine has the effects of tonifying heart and kidney, tonifying liver and strengthening spleen and stomach, and can adjust the functions of Qi and blood of human viscera, reinforce Qi and nourish blood, and quite spirit and stabilize mind, aiming at realizing the health function of improving sleeping with the coordination of a plurality of links. The medicine has the advantages of being small in toxic and side effects, treating both symptoms and root causes, and being obvious in treatment effect, fast to remove clinical symptoms, and no relapse after curing.

The invention discloses a human secretory FNDC5 protein as well as a preparation method and application thereof, and relates to the technical field of gene engineering. The human secretory FNDC5 protein does not contain a transmembrane structural domain and can be directly secreted and released into blood. The human secretory FNDC5 protein can be used for preparing medicines for treating atherosclerosis, medicines for promoting bone formation and medicines for treating aplastic anemia, and can be used for preparing endothelial cell proliferation medicines. After fasting injection is conductedon a high-fat fed obese mouse model, the human secretory FNDC5 protein can effectively reduce the weight of an obese mouse, which shows that the protein can obviously improve body fat metabolism of anobese patient and obviously reduce the levels of plasma cholesterol, free fatty acid and triglyceride, and shows that the protein can obviously improve lipid metabolism disorder of the obese patient.

A composition for prevention and treatment of metabolic syndromes is composed of radix astragali preparata, rhizoma polygonati, mulberry fruits, yam, fructus crataegi, lotus leaves, cassia seeds, phaseolus calcaratus, poria cocos, endothelium corneum gigeriae galli, fructus amomi, dandelions and the like. It is verified that the composition has the functions of relieving and preventing the metabolic syndromes such as abdominal obesity, dyslipidemia and abnormal glucose metabolism.

The invention relates to a method for using soft-shelled turtle ovum to prepare the drug that treats diabetes and reduce blood sugar, wherein soft-shelled turtle ovum comprises protein, unsaturated fatty acid, Omega-3 multi unsaturated fatty acid (EPA, DHA), and anti-oxidization nutrient (vitamin E), etc. the test has proves that: the diabetes mouse caused by alloxan that eats said drug can reduce blood sugar and release high triglyceride content and high cholesterol content. The invention can significantly treat fatty metabolic disorder, etc.

The invention relates to a fat-reducing composition. The fat-reducing composition contains the following raw materials in parts by weight: 30-40 parts of aronia melanocarpa fruit juice powder, 10-20 parts of medium chain triglyceride micro-capsule powder, 10-20 parts of towel gourd powder, 3-13 parts of Akkermansia muciniphila and 10-20 parts of fructo-oligosaccharide. The medium chain triglyceride micro-capsule powder and the aronia melanocarpa fruit juice powder in the fat-reducing composition are compounded so as to burn fat, inhibit fat synthesis and reduce accumulation of the fat in a human body, so that a synergetic fat-reducing effect is achieved; by virtue of synergism of Akk bacteria and the towel gourd powder, intestinal florae are regulated, and an effect of controlling the bodyweight is achieved; by virtue of synergism of polyphenol in the aronia melanocarpa fruit juice powder and the fructo-oligosaccharide, the abundance of the Akk bacteria is increased, and a fat-reducing effect is achieved. By integrating the effects of the five components, the fat-reducing composition is reasonable in compatibility, safe and effective; and the components generate a synergistic effect in different ways, so that the burning of the fat is accelerated, the intestinal florae are regulated, and the fat-reducing effect is relatively efficient.

The invention provides a lactobacillus plantarum Q16 capable of relieving non-alcoholic fatty liver function caused by high fat diet, the classification name of the lactobacillus plantarum is lactobacillus plantarum, the lactobacillus plantarum is preserved in China Center for Type Culture Collection on October 22, 2021, the address is Wuhan University, Wuhan, China, the postcode is 430072, and the preservation number is CCTCC NO: M20211311. The strain can effectively reduce the body weight, liver weight and fat weight of a high-fat diet mouse, improve lipid metabolism in the liver, inhibit accumulation of triglyceride and improve energy metabolism in the liver; in addition, the strain also has the capability of optimizing the intestinal flora structure, and has a good probiotic function.

The invention discloses an application of formononetin to treatment of nonalcoholic fatty liver disease. An in vitro and an in vitro cell model are adopted, formononetin is used for treating animals,and the improvement effect of the formononetin on metabolic syndromes of nonalcoholic fatty liver, obesity, insulin resistance, lipid disorders and the like can be observed. Experiment proves that theformononetin can notably reduce weight, liver weight/body mass indexes, liver triglyceride(TG), liver lipidoses, liver function damage criterion-millet straw aminopherase (AST) and alanine aminotransferase (ALT) of organisms suffering from nonalcoholic fatty liver, and besides, can improve insulin resistance. Blood biochemistry detection indicates that the formononetin can also reduce the level of triglyceride (TG), cholesterol (TC) and low intensity lipoprotein (LDL-C) of HFD mice, and can improve the lipid disorders. The formononetin has important effects on treatment of nonalcoholic fattyliver.

The invention discloses digestive yogurt containing modified starch and a preparation method thereof. The yogurt is prepared from the following raw materials in parts by weight: 80-120 parts of bovinecolostrum, 1-5 parts of the modified starch, 2-6 parts of fruit juice concentrate, 0.1-1 part of a sweetening agent, 0.1-1 part of probiotics and 0.5-1.5 parts of prebiotics, wherein the modified starch is composed of corn modified starch, cassava modified starch and potato modified starch according to a mass ratio of 1 to (3 to 5) to 2. The digestive yogurt containing the modified starch disclosed by the invention is rich in nutrition, and delicate and smooth in mouthfeel, has the functions of regulating the balance of human intestinal microecology, improving intestinal function, aiding digestion, reducing lipids and blood pressure, enhancing human immunity, and resisting aging, and is suitable for children, the aged and diabetics to eat; meanwhile, the preparation method of the yogurt is simple and practicable, strong in operability, low in cost, and is suitable for industrialized production and application.

The invention provides a use of Berberis dasystachya Maxim. fruit polysaccharide in preparation of drugs, health products or foods for improving dyslipidemia. A research proves that Berberis dasystachya Maxim. fruit can improve dyslipidemia, reduce cholesterol (TC), triglyceride (TG) and low density lipoprotein (LDL), increase high density lipoprotein (HDL), improve dyslipidemia-related enzyme activity thereby improving lipoprotein lipase and hepatic lipase activity, reduce glutamic oxalacetic transaminase and glutamic-pyruvic transaminase activity, does not damage liver tissue, and can be used as a drug, a health product or a food used for improving dyslipidemia and having good safety.

The invention discloses composition containing salvia miltiorrhiza fat soluble ingredients and coenzyme Q10, a preparation method of the composition and a drug containing the composition. The composition is prepared from components in percentage by weight as follows: 8%-24% of the salvia miltiorrhiza fat soluble ingredients, 16%-23% of the coenzyme Q10, 1.2%-3% of vitamin K and 50%-74% of corn oil. The composition can correct lipid metabolism unbalance of a body, reduce generation of lipid peroxide and reduce activation of inflammatory factors, so that atherosclerosis of aorta and cognitive impairment are relieved, and the composition has the efficacy of relieving disturbance of lipid metabolism, promoting antioxidation, relaxing vascular smooth muscles, repairing vascular endothelial cells and preventing nerve cell injury caused by ischemia and hypoxia; besides, the composition is used for preparing the drug and can effectively prevent or/and treat cardiovascular diseases and vascular dementia.

The invention discloses vermicelli suitable for people with metabolic syndrome, and a preparation method of the vermicelli, belonging to the field of food processing. The vermicelli is prepared by taking barley flour fermented by using lactobacillus plantarum, and wheat flour as raw materials, wherein edible salt, edible sodium carbonate and vital gluten are added into the raw materials; the preparation method comprises the processes of kneading dough, carrying out curing calendering, carrying out secondary curing calendering, cutting into strips, drying in the air, packaging, and the like. The vermicelli is prepared by taking barley, which has rich nutritional value and prominent health care functions, as one raw material, and the barley is dried into powder after being fermented by using the lactobacillus plantarum, so that the biological transformation of nutrient substances is realized, and the vermicelli can help the people with the metabolic syndrome to lose weight and relieve the glucose and lipid metabolism disorder of the people with the metabolic syndrome after being eaten for a long time. The vermicelli realizes the complementary advantages of the barley flour fermented by using the lactobacillus plantarum, and the wheat flour, so that the barley flour fermented by using the lactobacillus plantarum supplements partial nutrients such as beta-glucan, phenolic compounds and mineral substances which are lacked by the wheat flour on the one hand, and rich gluten and excellent processing performance of the wheat flour make up the defect that the barley flour fermented by using the lactobacillus plantarum cannot easily form a gluten structure on the other hand. Furthermore, in the process of fermenting the barley flour by using the lactobacillus plantarum, functional polypeptide is formed by means of proteolysis, so that a contribution is made to the use of the vermicelli.

The invention relates to the field of lipid reduction based on Kaempferol 3-O-2''-(6'''-p-coumaroyl) glucosylrhamnoside (KCGR) and discloses application of the KCGR in preparation of drugs capable ofinhibiting PCSK9 targets. It is discovered for the first time that the KCGR has the specificity of inhibiting the combination activity of PCSK9 and LDLR and can be compatibly combined in an active pocket area of a PCSK9 crystal structure and form stable hydrogen bonds with multiple amino acid residues, and therefore the KCGR is a novel micromolecular inhibitor for the PCSK9. The KCGR can lower thelevel of TC, TG and TDL-C in plasma of a hyperlipidaemia model mouse and raise the level of HDL-C, has the effect of alleviating lipid metabolism disorder caused by hyperlipidaemia and can be used for preventing or treating cardiovascular diseases and hyperlipidaemia.